Physicians' Academy for Cardiovascular Education

Atrial fibrillation

NOAC as possible treatment option in patients with AF after successful TAVI

5' education - Sep. 13, 2021 - Prof. Nicolas van Mieghem, MD, PhD

Head-to-head comparison of risk scores for ischemic stroke in patients with AF and CKD

5' education - June 14, 2001 - Ype de Jong, MD

Updates in the 2020 AF guidelines

3' education - Sep. 2, 2020 - Prof. Isabelle van Gelder, MD

Early rhythm control in AF patients improves outcomes

3' education - Aug. 29, 2020 - Prof. Paulus Kirchhof, MD

Oral anticoagulant monotherapy reduces bleeding in AF patients after TAVI

3' education - Mar. 30, 2020 - Dr. Jur ten Berg, MD, PhD - ACC 2020

Challenges in prescribing DOACs for stroke prevention in AF

5' education - Mar. 2, 2020 - Prof. Freek Verheugt and John Eikelboom

Smartphone-based AF screening in the general population

5' education - Oct. 28, 2019 - Paris, France - Tine Proesmans

Clear results with NOAC monotherapy in patients with CAD and AF

3' education - Sep. 2, 2019 - Prof. Freek Verheugt

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD

Proof-of-concept study shows 84% true AF in those with irregular pulse detected with smartwatch

3' education - Mar. 16, 2019 - New Orleans, LA, USA - Michael Valentine, MD

Population screening for atrial fibrillation with a smartphone

10' education - Aug. 26, 2018 - Munich, Germany - Prof. dr. Pieter Vandervoort - Genk, Belgium

Atrial fibrillation & HFpEF: Novel device and therapeutic approaches

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Dipak Kotecha - Birmingham, UK - Online CME

Considerations on antithrombotic treatment of VTE and AF patients

10' education - Mar. 8, 2018 - Prof. Menno Huisman and dr. Alexander Cohen

Neurotoxin injection did not prevent the common complication of AF after cardiac surgery

3' education - Nov. 15, 2017 - AHA 2017 - Anaheim, CA, USA - Nathan Waldron, MD - Durham, NC, USA.

Initiating digoxin in AF patients associated with early hazard of sudden death

3' education - Mar. 19, 2017 - ACC 2017, Washington, DC, USA - Dr. Renato Lopes

Tailoring oral anticoagulation in elderly patients with AF

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Christopher B. Granger, MD (Durham, NC, USA)

Outstanding questions and ongoing studies on the use of NOACs

3' education - Oct. 7, 2016 - Berg en Dal, The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA)

Oral anticoagulation in daily clinical practice in varous patient populations

10' education - Oct. 6, 2016 - The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA) and Marc Brouwer, MD (Nijmegen, The Netherlands)

Inadequate anticoagulant treatment for stroke prevention in atrial fibrillation

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Christian T. Ruff, MD - Boston, MA, USA
##SCROLLER_ITEMS_FULL_TITLE##

Where are we with HF patients with AF?

3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Dipak Kotecha
##SCROLLER_ITEMS_FULL_TITLE##

Translating new clinical trial data of DOACs for stroke prevention into clinical practice

3' education - Mar. 30, 2014 - VBWG at ACC - Michael Ezekowitz MD, PhD

Under- and overdosing of DOACs still common in patients with AF

Literature - Sep. 27, 2021 - Moudallel S et al. - Br J Clin Pharmacol. 2021

This study found inappropriate DOAC prescriptions in 16.9% of hospitalized patients with AF, with underdosing being more common than overdosing. Moreover, this study identified determinants of DOAC under- and overdosing.

NOAC as possible treatment option in patients with AF after successful TAVI

5' education - Sep. 13, 2021 - Prof. Nicolas van Mieghem, MD, PhD
In the ENVISAGE-TAVI AF trial, the effect of edoxaban on net adverse clinical events (NACE)  was compared to VKAs in elderly patients with AF who underwent TAVI.

ESC 2021 In the ENVISAGE-TAVI AF trial, the effect of edoxaban on net adverse clinical events (NACE) was compared to VKAs in elderly patients with AF who underwent TAVI.

Continuous monitoring for unknown AF and OAC if indicated does not prevent stroke

News - Aug. 29, 2021

ESC 2021 The LOOP study showed that continuous heart rhythm monitoring using an implantable loop recorder and initiation of OAC if AF was detected, did not prevent stroke in patients at high risk compared to standard care.

NOAC non-inferior to VKA for net adverse clinical events in AF patients after TAVI

News - Aug. 28, 2021

ESC 2021 Non-inferiority was met for edoxaban when compared with VKA for net adverse clinical events (NACE) in patients with AF after TAVI, but major bleeding was higher in those receiving edoxaban.

Clinical effects sGC stimulator in HFrEF after a worsening HF event unaffected by AF status

News - July 5, 2021

ESC HF 2021 This analysis of the VICTORIA trial showed that the beneficial effects of vericiguat were unaffected by AF status at baseline.

Myosin activator less effective in patients with HFrEF and AF or atrial flutter

News - July 2, 2021

ESC HF 2021 This subanalysis of the GALACTIC-HF trial showed that omecamtiv mecarbil treatment was less effective in HFrEF patients with baseline AF or atrial flutter (AFL), and this was prominent in digoxin treated patients with AF/AFL.

AF more often detected by implantable vs. external loop recorder after stroke

Literature - June 22, 2021 - Buck BH et al. - JAMA. 2021

A randomized clinical trial compared the rate of detection of AF with use of an implantable loop recorder for 12 months vs. use of an external loop recorder for 30 days in patients with recent ischemic stroke without known AF.

Omega-3 fatty acids supplementation associated with increased risk of incident AF

Literature - June 15, 2021 - Lombardi M et al. - Eur Heart J Cardiovasc Pharmacother. 2021

This meta-analysis of five RCTs (REDUCE-IT, ASCEND, R&P, STRENGTH and OMEMI) showed that omega-3 fatty acids supplementation is associated with an increased risk of incident AF, compared to placebo.

Biomarkers of inflammation predict HF hospitalization and adverse outcomes in AF

Literature - June 14, 2021 - Benz AP, et al. - J Am Heart Assoc. 2021

This combined cohort study suggested that IL-6 and hs-CRP levels were associated with HF hospitalization and adverse outcomes in patients with AF. The risk for HF hospitalization increased with increasing inflammation scores of both inflammation markers.

Head-to-head comparison of risk scores for ischemic stroke in patients with AF and CKD

5' education - June 14, 2001 - Ype de Jong, MD
The predictive performance of six risk scores for ischemic stroke in patients with AF and CKD were validated. The Modified CHADS2 score showed good performance for discrimination and calibration in all kidney function categories.

The predictive performance of six risk scores for ischemic stroke in patients with AF and CKD were validated. The Modified CHADS2 score showed good performance for discrimination and calibration in all kidney function categories.

No significant difference in outcomes with ablation-based rhythm control vs. rate control in patients with AF and HF

News - May 27, 2021

ACC 2021 Ablation-based rhythm control and rate control showed no statistically significant differences in the RAFT-AF trial for the primary outcome of all-cause mortality and HF events in patients with HF and high burden AF.

Alcohol consumption associated with greater odds of a discrete AF episode in the next four hours

News - May 19, 2021

ACC 2021 Results from the HOLIDAY study suggest that just one alcoholic drink was associated with a 2-fold greater odds and two or more alcoholic drinks were associated with a 3.5-fold greater odds of a discrete AF episode occurring in the next four hours.